Dostarlimab (Jemperli): A Comprehensive Clinical and Scientific Monograph

1.0 Executive Summary

Dostarlimab, marketed under the brand name Jemperli, is a humanized immunoglobulin G4 (IgG4) monoclonal antibody that has emerged as a pivotal therapeutic agent in the field of immuno-oncology. As a programmed death receptor-1 (PD-1) blocking antibody, dostarlimab functions by reinvigorating the host's immune system to combat malignant cells. Its mechanism hinges on high-affinity binding to the PD-1 receptor on T-cells, thereby preventing its interaction with ligands PD-L1 and PD-L2 and releasing the "brake" on anti-tumor immunity.

The clinical development of dostarlimab has been marked by rapid and significant success, particularly in cancers characterized by a deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) biomarker status. Landmark clinical trials have established dostarlimab as a new standard of care in endometrial cancer (EC). The GARNET study demonstrated robust and exceptionally durable responses for dostarlimab monotherapy in patients with previously treated, advanced dMMR EC. Subsequently, the RUBY trial established its role in the first-line setting, where its addition to chemotherapy conferred a profound survival benefit in patients with dMMR/MSI-H primary advanced or recurrent EC and also improved overall survival in the broader all-comer population, leading to expanded global approvals.

Beyond endometrial cancer, dostarlimab has produced unprecedented results in a phase II study for locally advanced dMMR rectal cancer, achieving a 100% clinical complete response rate and heralding a potential paradigm shift toward non-operative, curative-intent management. This has been complemented by a tumor-agnostic accelerated approval for the treatment of any dMMR solid tumor that has progressed on prior therapy.

The safety profile of dostarlimab is consistent with its drug class, characterized primarily by immune-mediated adverse reactions (IMARs) that can affect any organ system. These reactions, while potentially severe, are generally manageable with established protocols involving corticosteroids. The pharmacokinetic profile, notable for a long elimination half-life of approximately 25 days, supports a convenient every-six-week maintenance dosing schedule, reducing the treatment burden for patients.

This report provides a comprehensive analysis of dostarlimab, synthesizing data on its pharmacology, pivotal clinical trial results, safety profile, regulatory history, and comparative positioning. It aims to serve as an exhaustive scientific and clinical monograph for this important antineoplastic agent.

2.0 Molecular Profile and Pharmacology

2.1 Drug Identification and Structural Characteristics

Dostarlimab is a biologic therapeutic agent classified as a protein-based therapy.[1] It is a humanized monoclonal antibody of the IgG4 kappa isotype, produced using recombinant DNA technology in a mammalian cell line (Chinese Hamster Ovary, CHO).[2] In the United States, its non-proprietary name is often listed as dostarlimab-gxly, a convention used for certain biologics to distinguish them from potential future biosimilars.[5] The drug was developed under several internal codes, including TSR-042, GSK-4057190A, and ANB011.[8] Its fundamental properties are summarized in Table 2.1.

Table 2.1: Key Drug Identification and Properties

Property	Detail	Source(s)
Non-proprietary Name	Dostarlimab, Dostarlimab-gxly	5
Proprietary Name	Jemperli®	9
DrugBank Accession Number	DB15627	1
CAS Registry Number	2022215-59-2	10
Drug Class	Anti-PD-1 Monoclonal Antibody, Immune Checkpoint Inhibitor, Antineoplastic Agent	6
Molecular Type	Humanized IgG4 kappa Monoclonal Antibody	1
Manufacturing	Recombinant DNA technology in Chinese Hamster Ovary (CHO) cells	3

2.2 Mechanism of Action: High-Affinity Blockade of the PD-1/PD-L1 Axis

The therapeutic activity of dostarlimab is rooted in its function as an immune checkpoint inhibitor.[2] The core of its mechanism is the specific and high-affinity binding to the PD-1 receptor, which is expressed on the surface of activated T-cells.[13] In a healthy immune system, the PD-1 pathway acts as a crucial negative feedback loop to maintain self-tolerance and modulate the intensity and duration of immune responses, preventing autoimmunity.[14] Some cancer cells exploit this natural regulatory mechanism to evade immune destruction. They achieve this by overexpressing the ligands for PD-1, namely Programmed Death-Ligand 1 (PD-L1) and Programmed Death-Ligand 2 (PD-L2).[2] When these ligands bind to the PD-1 receptor on T-cells, they deliver a potent inhibitory signal that leads to T-cell exhaustion and apoptosis, effectively creating an immunosuppressive tumor microenvironment.[14]

Dostarlimab acts by physically obstructing this interaction. It binds to the PD-1 receptor and competitively inhibits its engagement with both PD-L1 and PD-L2.[16] This blockade removes the suppressive signal, thereby "releasing the brake" on T-cell activity.[14] The result is the restoration of T-cell proliferation, cytokine production (such as Interleukin-2 and Interferon-gamma), and cytotoxic T-lymphocyte (CTL) activity, enabling the immune system to once again recognize and mount an effective attack against tumor cells.[13]

The efficacy of this blockade is underpinned by dostarlimab's exceptional binding affinity. Laboratory studies have quantified this potency, showing half-maximal inhibitory concentrations (IC50​) of 1.8 nM for blocking the PD-1/PD-L1 interaction and 1.5 nM for the PD-1/PD-L2 interaction.[20] Furthermore, its equilibrium dissociation constant (

Kd​), a measure of binding strength, for human PD-1 is approximately 0.3 nM.[8] These sub-nanomolar and low-nanomolar values signify an extremely tight and durable bond between dostarlimab and the PD-1 receptor. This potent binding allows dostarlimab to effectively outcompete the natural ligands, ensuring a near-complete and sustained blockade of the checkpoint pathway. This robust molecular activity provides a direct biological rationale for the durable clinical responses observed in pivotal trials, where many patients experience long-term disease control.[7]

2.3 Pharmacodynamics: In Vitro and In Vivo Evidence of T-Cell Reactivation

The pharmacodynamic effects of dostarlimab confirm that its high-affinity molecular binding translates into a functional biological response. In vitro cellular assays have demonstrated that dostarlimab treatment leads to potent T-cell activation. In a human CD4+ T-cell mixed lymphocyte reaction (MLR) assay, dostarlimab increased Interleukin-2 (IL-2) production with a half-maximal effective concentration (EC50​) of approximately 1 nM.[20] In staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMCs), the

EC50​ for IL-2 production was even lower, at approximately 0.1 nM.[8] Furthermore, dostarlimab enhances antigen-specific T-cell activation, as shown by an increase in interferon-gamma (IFN-γ) release with an

EC50​ of approximately 0.5 nM.[15] Importantly, dostarlimab does not elicit non-specific T-cell responses in the absence of an antigen, confirming that it functions as a true checkpoint blocker rather than a non-specific T-cell agonist.[15]

This cellular activity has been shown to alter the tumor microenvironment in a manner favorable to anti-tumor immunity. In preclinical in vivo studies using an A549 lung cancer model, treatment with dostarlimab resulted in significant tumor growth inhibition of 62% at study termination compared to controls.[20] This anti-tumor activity was directly associated with pharmacodynamic changes within the tumor itself, including an increased infiltration of tumor-killing CD8+ T-cells and a concurrent reduction in the population of immunosuppressive regulatory T-cells (Tregs).[20] This chain of evidence—from high-affinity binding to functional T-cell activation and finally to a pro-inflammatory shift in the tumor microenvironment—provides a comprehensive, multi-level validation of the drug's mechanism of action prior to clinical application.

2.4 Clinical Pharmacokinetics: Administration, Distribution, and Elimination Profile

Dostarlimab is administered via intravenous (IV) infusion over a period of 30 minutes.[1] Its pharmacokinetics (PK) are linear in the dose range of 1 mg/kg to 10 mg/kg.[19] The drug's behavior in the body has been characterized in patients with various solid tumors, including endometrial cancer.[24]

Following the initial dosing regimen of 500 mg every 3 weeks, the mean maximum concentration (Cmax​) is 171 mcg/mL. During the maintenance phase of 1000 mg every 6 weeks, the mean Cmax​ reaches 309 mcg/mL.[1] The mean volume of distribution (

Vd​) at steady-state is approximately 5.3 L.[2] This relatively small volume of distribution suggests that the drug is primarily confined to the vascular and interstitial compartments, consistent with a large molecule like a monoclonal antibody.

As a protein, dostarlimab is not metabolized by cytochrome P450 enzymes or other traditional drug metabolism pathways. Instead, it is expected to be degraded into small peptides and amino acids via non-specific catabolic pathways throughout the body.[1] The mean clearance (CL) of dostarlimab at steady-state is low, at 0.007 L/h.[1] This slow clearance contributes to a long mean terminal elimination half-life (

t1/2​) of 25.4 days.[1]

This extended half-life is a critical pharmacokinetic feature that directly enables the convenient maintenance dosing schedule of 1000 mg every 6 weeks (Q6W).[13] A dosing interval of 42 days is approximately 1.6 times the drug's half-life, an interval that maintains drug concentrations well within the therapeutic window. This less frequent dosing regimen represents a significant quality-of-life benefit for patients, reducing the burden of treatment by minimizing the frequency of clinic visits compared to more common three- or four-week cycles for other cancer therapies.

No clinically significant differences in the pharmacokinetics of dostarlimab have been observed based on age (24 to 86 years), sex, race, tumor type, or in patients with renal or hepatic impairment.[24] A summary of key pharmacokinetic parameters is provided in Table 2.2.

Table 2.2: Summary of Dostarlimab Pharmacokinetic Parameters

Parameter	Value	Source(s)
Administration Route	Intravenous Infusion	23
Infusion Time	30 minutes	1
Volume of Distribution (Vd​)	~5.3 L	2
Clearance (CL)	~0.007 L/h	1
Elimination Half-Life (t1/2​)	~25.4 days	1
Metabolism	Catabolic pathways	1

3.0 Clinical Efficacy and Therapeutic Applications

3.1 Endometrial Cancer: Establishing a New Standard of Care

Dostarlimab has fundamentally altered the treatment landscape for endometrial cancer (EC), a common gynecologic malignancy that arises from the lining of the uterus.[9] Its efficacy has been proven in two pivotal clinical trials, GARNET and RUBY, leading to its establishment as a new standard of care in both previously treated and frontline settings.

3.1.1 The GARNET Study: Efficacy of Monotherapy in Previously Treated dMMR/MSI-H Disease

The GARNET trial (NCT02715284) was a multicenter, single-arm, open-label phase I/II study that provided the foundational evidence for dostarlimab's utility in EC.[7] The trial evaluated dostarlimab monotherapy in patients with advanced solid tumors, with a specific expansion cohort (A1) dedicated to patients with dMMR/MSI-H advanced or recurrent EC whose disease had progressed on or after a platinum-containing chemotherapy regimen.[26]

In an efficacy population of 141 patients from this cohort, dostarlimab demonstrated impressive and durable anti-tumor activity.[7] Based on a blinded independent central review (BICR) with a median follow-up of 27.9 months, the key results were as follows [7]:

• Objective Response Rate (ORR): The confirmed ORR was 45.5% (95% CI: 37.1-54.0).
• Complete and Partial Response: The response was comprised of a 15.6% complete response (CR) rate and a 29.8% partial response (PR) rate.
• Duration of Response (DOR): The median DOR was not reached, signifying long-lasting benefit. At the time of analysis, 85.9% of responding patients had a response lasting for 12 months or longer, and 54.7% had a response lasting for 24 months or longer.

Efficacy was observed consistently across patient subgroups, including those who had received one prior line of therapy (ORR 43.8%) and those who were more heavily pre-treated with two or more prior lines (ORR 48.1%).[28] The most compelling finding from GARNET was not merely the response rate but the profound durability of these responses. With a median DOR not reached at over two years of follow-up, the data suggest that for the nearly half of patients who respond, dostarlimab can induce a long-term, stable disease control. This represents a significant clinical achievement, potentially transforming what was a progressively fatal disease into a chronic, manageable condition for this biomarker-defined subset of patients. These results led to the initial regulatory approvals for dostarlimab in this setting.[7]

Table 3.1: Summary of Efficacy Results from the GARNET Trial (Cohort A1)

Endpoint	Result (N=141)	95% Confidence Interval	Source(s)
Objective Response Rate (ORR)	45.5%	37.1% - 54.0%	7
Complete Response (CR) Rate	15.6%	-	7
Partial Response (PR) Rate	29.8%	-	7
Median Duration of Response (DOR)	Not Reached	-	7
% Responders with DOR ≥12 months	85.9%	-	7
% Responders with DOR ≥24 months	54.7%	-	7

3.1.2 The RUBY Study: Frontline Combination Therapy and Expansion to All-Comer Population

Building on the success of GARNET, the RUBY trial (NCT03981796) evaluated dostarlimab in the first-line setting.[9] This randomized, double-blind, placebo-controlled phase III trial compared dostarlimab plus standard-of-care chemotherapy (carboplatin and paclitaxel) against placebo plus chemotherapy in patients with primary advanced or recurrent EC.[29] The trial's design allowed for analysis in both a pre-specified dMMR/MSI-H subgroup and the overall (all-comer) population, yielding practice-changing results for both.

• dMMR/MSI-H Population: In the subgroup of 122 patients with dMMR/MSI-H tumors, the addition of dostarlimab to chemotherapy resulted in a dramatic and statistically significant improvement in progression-free survival (PFS). The median PFS was 30.3 months in the dostarlimab arm compared to just 7.7 months in the placebo arm, corresponding to a 71% reduction in the risk of disease progression or death (Hazard Ratio = 0.29; 95% CI: 0.17-0.50; p<0.0001).[29] The 2-year PFS rate was 61.4% with dostarlimab versus 15.7% with placebo.[31]
• Overall Population: The trial also met its key secondary endpoint of overall survival (OS) in the total study population. The addition of dostarlimab resulted in a median OS of 44.6 months, compared to 28.2 months in the placebo arm (HR = 0.69; 95% CI: 0.54-0.89; p=0.002).[30]

The magnitude of benefit demonstrated in the RUBY trial has redefined the first-line standard of care for advanced or recurrent EC. The profound benefit in the dMMR population (HR 0.29 for PFS) is so large that it effectively mandates the inclusion of dostarlimab with chemotherapy for these patients. Concurrently, the statistically significant OS benefit observed in the overall population, while heavily influenced by the dMMR subgroup, was robust enough to convince regulatory agencies like the U.S. FDA and the European Commission to expand the approval to all patients with primary advanced or recurrent EC, regardless of their MMR status.[32] This has fundamentally changed the treatment algorithm for a much larger group of patients than initially targeted.

Table 3.2: Key Efficacy Outcomes from the RUBY Trial (dMMR/MSI-H and Overall Populations)

Population	Endpoint	Dostarlimab + Chemo Arm	Placebo + Chemo Arm	Hazard Ratio (95% CI)	p-value	Source(s)
dMMR/MSI-H	Median PFS	30.3 months	7.7 months	0.29 (0.17, 0.50)	<0.0001	29
Overall	Median OS	44.6 months	28.2 months	0.69 (0.54, 0.89)	0.002	30

3.2 Locally Advanced Rectal Cancer: A Potential Curative-Intent Paradigm

Dostarlimab has generated unprecedented results in a population outside of its primary indication. A phase II investigator-initiated trial conducted at Memorial Sloan Kettering Cancer Center (MSK) evaluated dostarlimab monotherapy as a neoadjuvant (pre-surgical) treatment for patients with locally advanced dMMR rectal cancer.[22] The standard of care for this disease typically involves a grueling regimen of chemotherapy, radiation, and major surgery, often resulting in permanent colostomy and significant long-term morbidity.[35]

The results from this trial were remarkable. An initial report on the first 12 patients, published in The New England Journal of Medicine, showed a 100% clinical complete response (cCR) rate.[2] Updated, longer-term data presented at the 2024 ASCO Annual Meeting confirmed and extended this finding, showing a 100% cCR rate in all 42 patients who had completed treatment.[22] This response was defined as no evidence of tumor on magnetic resonance imaging (MRI), endoscopy, and digital rectal exam.[22]

Crucially, every patient who achieved a cCR was able to forgo subsequent chemoradiation and surgery.[6] The responses have proven to be durable, with a median follow-up of 26.3 months in the first 24 patients, and some responses have been sustained for as long as five years.[22] These findings represent more than just high efficacy; they signal a potential paradigm shift toward non-operative management and organ preservation. If these results can be replicated in larger, ongoing registrational trials such as AZUR-1 and AZUR-2, dostarlimab could establish a new curative-intent treatment pathway that eliminates the need for life-altering surgery and toxic radiation for this patient subset, representing a transformative improvement in survivorship and quality of life.[22]

3.3 Pan-Tumor Indication: dMMR/MSI-H Recurrent or Advanced Solid Tumors

Reflecting a broader shift in oncology toward biomarker-driven therapy, dostarlimab received accelerated approval from the FDA for a tumor-agnostic indication.[9] This approval covers the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.[1]

This approval was based on data from the GARNET study, which included a cohort (F) for non-endometrial dMMR solid tumors.[27] This pan-tumor indication underscores the principle that the genetic biomarker of dMMR/MSI-H is a more powerful predictor of response to PD-1 blockade than the anatomical site of the cancer's origin. Tumors with this biomarker have a defective DNA repair mechanism, leading to a very high number of mutations and the generation of tumor neoantigens.[15] These neoantigens make the cancer cells highly "visible" to a reawakened immune system, explaining the high response rates to checkpoint inhibitors across different tumor types, including gastric and colorectal cancers.[38] This approval emphasizes the critical importance of universal biomarker testing for all patients with advanced cancer to identify those who may be candidates for this highly effective therapy.[35] As an accelerated approval, continued approval for this indication is contingent upon verification of clinical benefit in confirmatory trials.[1]

3.4 Investigational Landscape: Ongoing and Future Clinical Trials

The clinical development program for dostarlimab is extensive and continues to expand, aiming to build on its established successes and explore new frontiers.[40] A primary focus is on confirming the groundbreaking results in rectal cancer through larger, registrational studies. The AZUR-1 trial is investigating dostarlimab monotherapy as a replacement for standard neoadjuvant therapy in dMMR/MSI-H locally advanced rectal cancer, while the AZUR-2 trial is evaluating perioperative dostarlimab in resectable dMMR/MSI-H colon cancer.[22]

Beyond colorectal cancer, dostarlimab is being actively studied in a wide range of other malignancies. Active phase II trials are recruiting patients with gastric adenocarcinoma [38], and other studies are exploring its use in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma, and melanoma.[40]

A significant portion of the investigational strategy involves evaluating dostarlimab in rational combination regimens designed to overcome resistance and enhance efficacy. Trials are underway combining dostarlimab with other immunotherapies, such as the TIM-3 inhibitor cobolimab, based on the rationale that dual checkpoint blockade may be synergistic.[40] Another key area is the combination with targeted therapies, such as PARP inhibitors (niraparib) in cervical and penile cancer.[40] The scientific basis for this approach is that PARP inhibitors can induce DNA damage and genomic instability, potentially increasing the immunogenicity of tumors and making them more susceptible to PD-1 blockade. This broad and scientifically driven clinical trial program demonstrates a clear strategy: first, to solidify and expand its use in dMMR/MSI-H tumors, and second, to push the boundaries of immunotherapy by exploring novel combinations to tackle more challenging and resistant cancers.

4.0 Comprehensive Safety and Tolerability Profile

As with all immune checkpoint inhibitors, the therapeutic benefit of dostarlimab is accompanied by a unique spectrum of potential adverse effects, primarily immune-mediated adverse reactions (IMARs). Understanding and managing this safety profile is paramount for its safe and effective use.

4.1 Characterization and Management of Immune-Mediated Adverse Reactions (IMARs)

The mechanism of action of dostarlimab—releasing the brakes on the immune system—inherently carries the risk of inducing an overactive immune response that can target healthy tissues.[1] These IMARs can be severe or fatal, can occur at any time during or after treatment, and can affect any organ system or tissue.[1]

Prompt recognition and management are critical. The general management principle is based on the severity of the reaction, graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE). For suspected IMARs, dostarlimab should be withheld, and appropriate workup should be initiated to exclude other causes, such as infection.[6] For moderate (Grade 2) reactions, treatment typically involves withholding dostarlimab and initiating systemic corticosteroids (e.g., prednisone 1 to 2 mg/kg/day or equivalent). For severe (Grade 3) or life-threatening (Grade 4) reactions, dostarlimab should be permanently discontinued, and high-dose corticosteroids should be administered.[23] Once the reaction improves to Grade 1 or less, the corticosteroid dose should be tapered slowly over at least one month to prevent recurrence.[6] Specific dose modification recommendations are outlined in Table 4.1.

Table 4.1: Recommended Dose Modifications for Immune-Mediated Adverse Reactions

IMAR Type	Grade 2 Severity	Grade 3 or 4 Severity	Source(s)
Pneumonitis	Withhold	Permanently discontinue (or for recurrent Grade 2)	23
Colitis	Withhold	Withhold (Grade 3), Permanently discontinue (Grade 4)	3
Hepatitis	Withhold	Permanently discontinue	3
Endocrinopathies	Withhold until clinically stable	Withhold or permanently discontinue depending on severity	3
Nephritis with renal dysfunction	Withhold	Permanently discontinue	23
Exfoliative dermatologic conditions	Withhold (suspected SJS/TEN)	Permanently discontinue (confirmed SJS/TEN)	23
Myocarditis	Permanently discontinue	Permanently discontinue	23
Neurological toxicities	Withhold	Permanently discontinue	23

4.2 System-Specific IMARs: Incidence and Severity

Several specific IMARs have been reported in clinical trials with dostarlimab:

• Pneumonitis: Immune-mediated pneumonitis occurred in 2.3% to 4% of patients receiving dostarlimab, including cases that were Grade 3, Grade 4, or fatal.[6]
• Colitis: Immune-mediated colitis was reported in approximately 1.3% of patients, with some cases being Grade 3 in severity.[28] Cytomegalovirus (CMV) infection or reactivation has been noted in patients with corticosteroid-refractory colitis treated with PD-1 inhibitors.[17]
• Hepatitis: Immune-related liver injury can occur. While mild to moderate elevations in serum aminotransferases are relatively common (15-25% of recipients), severe immune-mediated hepatitis is less frequent. Grade 3 hepatitis occurred in 0.5% of patients, and serum ALT elevations greater than five times the upper limit of normal were seen in 2-3% of recipients.[9]
• Endocrinopathies: These are among the more common IMARs. Thyroid disorders are particularly frequent, with hypothyroidism reported in 8-12% of patients and hyperthyroidism in 2-5%.[19] Other endocrinopathies include adrenal insufficiency (~1.2%), hypophysitis (~0.2-0.4%), and type 1 diabetes mellitus (~0.2-0.4%).[9]
• Dermatologic Reactions: Immune-mediated rash or dermatitis is common. While most cases are mild to moderate, severe and life-threatening reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) have been reported with PD-1/PD-L1 blocking antibodies.[6]
• Other IMARs: A wide range of other clinically significant IMARs have been observed, though less frequently. These include nephritis with renal dysfunction, myocarditis, pericarditis, myositis, pancreatitis, and various neurological syndromes like meningitis, encephalitis, and Guillain-Barré syndrome.[6]

4.3 Common Adverse Events and Laboratory Abnormalities

Beyond the specific category of IMARs, dostarlimab is associated with a profile of more general adverse events (AEs). The profile differs depending on whether it is used as a single agent or in combination with chemotherapy. The overlap in toxicities between dostarlimab and chemotherapy creates a clinical challenge in correctly attributing symptoms. For example, a patient on combination therapy presenting with diarrhea requires careful evaluation to differentiate between a common chemotherapy side effect, which can be managed supportively, and potentially life-threatening immune-mediated colitis, which requires immediate drug cessation and immunosuppression.

• Monotherapy (from GARNET trial): The most common AEs (occurring in ≥20% of patients) were fatigue/asthenia, anemia, nausea, diarrhea, constipation, vomiting, and rash.[7] The most common Grade 3 or 4 laboratory abnormalities were decreased lymphocytes and decreased sodium.[28]
• Combination Therapy (from RUBY trial): The most common AEs (≥20%) included those expected from chemotherapy (peripheral neuropathy, alopecia, decreased hemoglobin/platelets/neutrophils) as well as those associated with dostarlimab, such as rash, diarrhea, and hypothyroidism.[28]

4.4 Warnings, Precautions, and Special Populations

• Infusion-Related Reactions: While uncommon, severe or life-threatening infusion-related reactions have been reported with PD-1/PD-L1 inhibitors. Severe (Grade 3) reactions occurred in 0.2% of patients receiving dostarlimab.[17] Management involves slowing, interrupting, or permanently discontinuing the infusion based on severity.[23]
• Embryo-Fetal Toxicity: Dostarlimab can cause fetal harm. As an IgG4 antibody, it can cross the placental barrier, and inhibition of the PD-1 pathway can lead to immune-mediated rejection of the developing fetus.[9] Females of reproductive potential must be advised of this risk and should use effective contraception during treatment and for 4 months after the final dose. Breastfeeding is also not recommended during this period.[6]
• Complications of Allogeneic HSCT: Patients who receive an allogeneic hematopoietic stem cell transplant (HSCT) either before or after treatment with a PD-1 inhibitor are at increased risk for serious and fatal complications, including graft-versus-host disease (GVHD).[6] The risks and benefits of treatment in this context must be carefully considered.

5.0 Comparative, Regulatory, and Economic Analysis

5.1 Global Regulatory Trajectory: FDA and EMA Approval Milestones

The regulatory history of dostarlimab illustrates a rapid and successful development pathway, progressing from a niche indication to a broad standard of care in a remarkably short timeframe. This trajectory was enabled by well-designed pivotal trials that demonstrated compelling efficacy in areas of high unmet medical need.

• U.S. Food and Drug Administration (FDA):
• April 2021: Dostarlimab received its first accelerated approval for adult patients with dMMR recurrent or advanced EC that had progressed on or after platinum-based chemotherapy, based on the GARNET trial data.[1]
• August 2021: A second accelerated approval was granted for the pan-tumor indication of dMMR recurrent or advanced solid tumors.[25]
• February 2023: With mature data from GARNET, the FDA converted the accelerated approval for dMMR EC to a full, regular approval.[7]
• July 2023: Based on the profound PFS benefit shown in the RUBY trial, the FDA approved dostarlimab in combination with carboplatin and paclitaxel for first-line treatment of primary advanced or recurrent dMMR/MSI-H EC.[29]
• August 2024: In a landmark decision based on the overall survival benefit demonstrated in the RUBY trial's all-comer population, the FDA expanded the combination therapy indication to include all adult patients with primary advanced or recurrent EC, regardless of MMR status.[9]
• European Medicines Agency (EMA):
• Dostarlimab was initially approved in the European Union for the treatment of dMMR/MSI-H recurrent or advanced EC as monotherapy after prior platinum therapy.[9]
• October 2023: The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended approval for dostarlimab in combination with chemotherapy for the first-line treatment of dMMR/MSI-H primary advanced or recurrent EC.[43]
• Late 2024/Early 2025: Following the RUBY trial's OS results, GSK announced that the European Commission had expanded the combination therapy approval to all adult patients with primary advanced or recurrent EC, including the MMR proficient (MMRp)/microsatellite stable (MSS) population.[33] The formal review process was initiated in mid-2024 with approval anticipated in the first half of 2025.[44]

This step-wise expansion, moving from an accelerated approval in a biomarker-defined subgroup to a full approval as a broad first-line standard of care in just over three years, serves as a model for efficient and impactful drug development.

5.2 Comparative Assessment: Dostarlimab versus Other PD-1 Inhibitors

While dostarlimab belongs to the same class as other established PD-1 inhibitors like pembrolizumab and nivolumab, emerging data suggest potential differences in binding, efficacy, and approved uses.

• Head-to-Head Clinical Data: Direct comparisons of checkpoint inhibitors are rare, making the phase II PERLA trial particularly valuable. This trial compared dostarlimab plus chemotherapy against pembrolizumab plus chemotherapy as a first-line treatment for metastatic non-squamous NSCLC.[41] The results showed a numerical trend favoring the dostarlimab-containing regimen across key efficacy endpoints, with a similar and manageable safety profile.

Table 5.1: Comparative Efficacy and Safety of Dostarlimab vs. Pembrolizumab in NSCLC (PERLA Trial)

Endpoint	Dostarlimab + Chemo Arm	Pembrolizumab + Chemo Arm	Hazard Ratio / Difference (95% CI)	Source(s)
Median PFS	8.8 months	6.7 months	HR 0.70 (0.50, 0.98)	41
Median OS	19.4 months	15.9 months	HR 0.75 (0.53, 1.05)	41
ORR	46%	37%	Difference 9%	45
Grade ≥3 TRAEs	36%	42%	-	45
Serious AEs	38%	45%	-	45

• Binding Mechanism and Affinity: While all three drugs block the PD-1 receptor, structural analyses reveal they bind to distinct epitopes. The binding modes of dostarlimab and another PD-1 inhibitor, cemiplimab, are strikingly similar to each other but are very different from those of pembrolizumab and nivolumab.[47] Dostarlimab also demonstrates a particularly high binding affinity for PD-1 ( Kd​ of 0.3 nM), which is stronger than that reported for nivolumab (Kd​ of 4.06 nM).[8] Whether these molecular differences translate into clinically meaningful distinctions in efficacy or safety across different tumor types remains an area of active research.
• Indications in Endometrial Cancer: In the context of EC, both dostarlimab and pembrolizumab are approved for use with chemotherapy in the first-line dMMR setting, and experts generally view the addition of a checkpoint inhibitor as beneficial regardless of which agent is used.[48] Head-to-head trials in this indication are considered unlikely.[48] However, their approvals in other EC settings differ: dostarlimab is approved for the all-comer population in combination with chemotherapy, while pembrolizumab is approved in combination with the tyrosine kinase inhibitor lenvatinib for the MMR proficient (pMMR) population after prior therapy.[48] Nivolumab is not a primary approved agent for EC but is being explored in clinical trials.[51]

5.3 Health Economic Considerations and Cost-Effectiveness

The significant clinical benefits of dostarlimab are accompanied by high acquisition costs, leading to complex health economic assessments that vary by patient population and healthcare system.

A cost-effectiveness analysis from the perspective of a United States payer found that dostarlimab in combination with chemotherapy is a cost-effective option for the first-line treatment of primary advanced or recurrent dMMR EC. The analysis yielded an incremental cost-effectiveness ratio (ICER) of approximately $60,349 per quality-adjusted life year (QALY) gained, a value that falls comfortably below the common willingness-to-pay threshold of $150,000 per QALY.[53]

However, for the pMMR EC population, the same analysis found that the combination was not cost-effective, with an ICER of approximately $175,788 per QALY.[53] This highlights a significant tension between regulatory approval and economic value. While the drug is approved for the all-comer population based on a statistically significant OS benefit, the magnitude of that benefit is smaller in the pMMR subgroup than in the dMMR subgroup. This results in a high cost per unit of clinical benefit gained, which may lead to reimbursement challenges and access hurdles for pMMR patients in certain healthcare systems.

The economic picture also varies globally. A similar analysis from the perspective of the Chinese healthcare system concluded that dostarlimab plus chemotherapy was unlikely to be a cost-effective option for advanced EC in either the dMMR or pMMR subgroups, given the local willingness-to-pay thresholds.[54]

6.0 Biopharmaceutical Manufacturing

6.1 Principles of Recombinant Monoclonal Antibody Production

Dostarlimab is classified as a "biotech" drug, meaning it is produced through a complex biological process rather than by traditional chemical synthesis.[55] This manufacturing process is intricate, multi-staged, and requires stringent control to ensure the final product's quality, safety, and efficacy.[55]

1. Cell Line Development: The process begins with genetic engineering. The DNA sequence encoding the humanized dostarlimab antibody is inserted into a host cell line, typically Chinese Hamster Ovary (CHO) cells, which are chosen for their ability to correctly produce and secrete complex human-like proteins.[3] These cells are then screened and selected to identify high-producing clones that will form the basis of the master cell bank.[55]
2. Upstream Processing: The selected cell line is cultivated in large-scale, sterile bioreactors. The cells are grown in a carefully optimized culture medium that provides all the necessary nutrients for cell growth and antibody production. Parameters such as temperature, pH, and dissolved oxygen are continuously monitored and controlled to maximize cell density and antibody yield.[55]
3. Downstream Processing: Once the desired antibody concentration is reached, the culture is harvested. The initial steps involve clarification, where cells and cellular debris are removed from the culture medium using techniques like centrifugation and filtration.[56] This is followed by a series of sophisticated purification steps, most notably affinity chromatography (e.g., using Protein A, which specifically binds to the Fc region of IgG antibodies), to isolate the dostarlimab antibody from other proteins and contaminants.[56]
4. Formulation and Fill-Finish: The highly purified antibody is then formulated into a stable, buffered solution suitable for intravenous administration. Finally, the drug product is aseptically filled into sterile vials, sealed, and packaged.[55]

This complex biological manufacturing process is a key reason for the high cost of monoclonal antibodies like dostarlimab. It also underscores the importance of proper storage and handling (e.g., refrigeration, use of specific infusion materials) to maintain the protein's structural integrity and biological activity.[10] Furthermore, because the final product is a large protein, there is an inherent risk of immunogenicity, where the patient's body may develop anti-drug antibodies (ADAs), which have the potential to affect the drug's pharmacokinetics and efficacy.[6]

7.0 Synthesis and Future Perspectives

Dostarlimab has firmly established itself as a major therapeutic advance in oncology, exemplifying the power of targeted immunotherapy. Its development showcases a successful translation of potent molecular pharmacology—characterized by high-affinity and durable PD-1 blockade—into profound and practice-changing clinical benefit. In the landscape of dMMR/MSI-H cancers, it has become a cornerstone therapy. For patients with advanced endometrial cancer, it has redefined the standard of care in both second-line and, most critically, first-line settings. For those with locally advanced rectal cancer, it has offered the unprecedented potential for a cure without the need for debilitating surgery or radiation.

The rapid regulatory trajectory of dostarlimab, moving from a niche accelerated approval to a broad, all-comer indication in a major cancer type, highlights its significant impact and the strength of the clinical data supporting its use. Furthermore, head-to-head data from the PERLA trial suggest it may have a competitive efficacy profile against the established market leader, pembrolizumab, in NSCLC, though further confirmation is needed.

Despite these successes, the story of dostarlimab is still unfolding, and several key questions will shape its future role in cancer therapy:

• Confirmation and Expansion in the Neoadjuvant Setting: Can the remarkable 100% complete response rate in dMMR rectal cancer be replicated in larger, registrational trials like AZUR-1? If so, can this organ-preserving, curative-intent paradigm be successfully expanded to other dMMR tumor types, such as colon or gastric cancer, in the neoadjuvant setting?
• Optimizing Use in the pMMR Population: While approved for all-comer endometrial cancer, the cost-effectiveness of dostarlimab in the pMMR subgroup is questionable. Future research must focus on identifying predictive biomarkers within this large population to select patients most likely to derive substantial benefit, thereby improving its therapeutic index and economic value.
• The Role of Combination Therapy: The future of immunotherapy lies in combination. The ongoing trials exploring dostarlimab with other checkpoint inhibitors (like anti-TIM-3) and targeted agents (like PARP inhibitors) are critical. The success of these combinations will determine whether dostarlimab's utility can be extended beyond the dMMR/MSI-H niche into the broader landscape of immunologically "cold" tumors.
• Positioning in Competitive Markets: Given the promising data from the PERLA trial, dostarlimab's future in the highly competitive NSCLC market will depend on further phase III data and strategic positioning. Differentiating itself based on efficacy, safety, or even the convenience of its Q6W dosing schedule will be crucial.

In conclusion, dostarlimab (Jemperli) is a powerful and effective PD-1 inhibitor that has already transformed the lives of patients with specific types of cancer. Its journey from a targeted agent for a niche biomarker to a broad standard of care is a testament to its efficacy and the success of its clinical development program. The ongoing research will continue to define its ultimate place in the armamentarium of cancer therapies, with the potential to bring durable responses and improved quality of life to an even wider range of patients.

Works cited

1. Dostarlimab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 30, 2025, https://go.drugbank.com/drugs/DB15627
2. Dostarlimab - PubChem, accessed July 30, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dostarlimab
3. Jemperli, INN-dostarlimab - EMA, accessed July 30, 2025, https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf
4. Jemperli Product Monograph - GSK.ca, accessed July 30, 2025, https://ca.gsk.com/media/6620/jemperli_pm.pdf
5. Dostarlimab-gxly (intravenous route) - Side effects & uses - Mayo Clinic, accessed July 30, 2025, https://www.mayoclinic.org/drugs-supplements/dostarlimab-gxly-intravenous-route/description/drg-20514856
6. Dostarlimab-gxly Monograph for Professionals - Drugs.com, accessed July 30, 2025, https://www.drugs.com/monograph/dostarlimab-gxly.html
7. FDA grants regular approval to dostarlimab-gxly for dMMR endometrial cancer, accessed July 30, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-dostarlimab-gxly-dmmr-endometrial-cancer
8. Dostarlimab | TSR-042 | Targeting CD19 - TargetMol, accessed July 30, 2025, https://www.targetmol.com/compound/dostarlimab
9. Dostarlimab - Wikipedia, accessed July 30, 2025, https://en.wikipedia.org/wiki/Dostarlimab
10. 2022215-59-2 | Dostarlimab - ChemScene, accessed July 30, 2025, https://www.chemscene.com/2022215-59-2.html
11. Dostarlimab Uses, Side Effects & Warnings - Drugs.com, accessed July 30, 2025, https://www.drugs.com/mtm/dostarlimab.html
12. Dostarlimab-gxly - NCI, accessed July 30, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/dostarlimab-gxly
13. Jemperli | European Medicines Agency (EMA), accessed July 30, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli
14. Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the ..., accessed July 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9694305/
15. Full article: Dostarlimab: From preclinical investigation to drug approval and future directions, accessed July 30, 2025, https://www.tandfonline.com/doi/full/10.1080/21645515.2023.2178220
16. go.drugbank.com, accessed July 30, 2025, https://go.drugbank.com/drugs/DB15627#:~:text=Dostarlimab%20is%20a%20monoclonal%20antibody,immune%20response%20to%20proceed%20unimpeded.
17. JEMPERLI (dostarlimab-gxly) injection 500 mg Mechanism of Action - GSK US, accessed July 30, 2025, https://us.gsk.com/media/6620/jemperli-branded-approval-media-fact-sheet-04-22-final.pdf
18. Dostarlimab (Jemperli) 2025 Updates: What Patients Need to Know? - Oncodaily, accessed July 30, 2025, https://oncodaily.com/drugs/dostarlimab-jemerli-patient-version
19. dostarlimab - Cancer Care Ontario, accessed July 30, 2025, https://www.cancercareontario.ca/en/system/files_force/dostarlimab.pdf?download=1
20. Dostarlimab (TSR-042) | Anti-PD-1 mAb - MedchemExpress.com, accessed July 30, 2025, https://www.medchemexpress.com/dostarlimab.html
21. Dostarlimab (TSR-042) | CAS 2022215-59-2 - AbMole BioScience, accessed July 30, 2025, https://www.abmole.com/products/dostarlimab.html
22. Jemperli (dostarlimab) trial continues to show unprecedented results ..., accessed July 30, 2025, https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-trial-continues-to-show-unprecedented-results/
23. Dosing & Administration | JEMPERLI (dostarlimab-gxly), accessed July 30, 2025, https://www.jemperlihcp.com/dosing-and-administration/
24. This label may not be the latest approved by FDA. For current ..., accessed July 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761174s000lbl.pdf
25. Jemperli (dostarlimab-gxly) FDA Approval History - Drugs.com, accessed July 30, 2025, https://www.drugs.com/history/jemperli.html
26. Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm, accessed July 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10493167/
27. GSK presents new data from the GARNET study demonstrating potential of dostarlimab to treat a subset of women with recurrent or advanced endometrial cancer, accessed July 30, 2025, https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-from-the-garnet-study-demonstrating-potential-of-dostarlimab-to-treat-a-subset-of-women-with-recurrent-or-advanced-endometrial-cancer/
28. GARNET Efficacy & Study Design | JEMPERLI (dostarlimab-gxly), accessed July 30, 2025, https://www.jemperlihcp.com/efficacy/garnet-trial/
29. FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer, accessed July 30, 2025, https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dostarlimab-gxly-chemotherapy-endometrial-cancer
30. FDA expands endometrial cancer indication for dostarlimab-gxly with chemotherapy, accessed July 30, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-endometrial-cancer-indication-dostarlimab-gxly-chemotherapy
31. Dostarlimab for the Treatment of Endometrial Cancer: A Review - touchONCOLOGY, accessed July 30, 2025, https://touchoncology.com/gynaecological-cancers/journal-articles/dostarlimab-for-the-treatment-of-endometrial-cancer-a-review/
32. FDA Expands Dostarlimab Approval for All Advanced Endometrial Cancers, accessed July 30, 2025, https://www.targetedonc.com/view/fda-expands-dostarlimab-approval-for-all-advanced-endometrial-cancers
33. European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer | GSK, accessed July 30, 2025, https://www.gsk.com/en-gb/media/press-releases/european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/
34. EMA Recommends Extension of Indications for Dostarlimab | ESMO, accessed July 30, 2025, https://www.esmo.org/oncology-news/ema-recommends-extension-of-indications-for-dostarlimab
35. Dostarlimab Delivers Impressive Results in Rectal Cancer, But More Research Needed, accessed July 30, 2025, https://www.targetedonc.com/view/dostarlimab-delivers-impressive-results-in-rectal-cancer-but-more-research-needed
36. Neoadjuvant PD-1 Blockade in Early-stage Mismatch Repair-deficient Cancers Can Eliminate the Need for Surgery Regardless of Tumor Type | News Releases | AACR, accessed July 30, 2025, https://www.aacr.org/about-the-aacr/newsroom/news-releases/neoadjuvant-pd-1-blockade-in-early-stage-mismatch-repair-deficient-cancers-can-eliminate-the-need-for-surgery-regardless-of-tumor-type/
37. JEMPERLI (dostarlimab-gxly) Review - accessdata.fda.gov, accessed July 30, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761223Orig1s000MultidisciplineR.pdf
38. Gastric Adenocarcinoma Recruiting Phase 2 Trials for Dostarlimab (DB15627) - DrugBank, accessed July 30, 2025, https://go.drugbank.com/indications/DBCOND0030814/clinical_trials/DB15627?phase=2&status=recruiting
39. Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review - PubMed, accessed July 30, 2025, https://pubmed.ncbi.nlm.nih.gov/40649207/
40. Clinical Trials Using Dostarlimab - NCI, accessed July 30, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/dostarlimab
41. Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial - PubMed Central, accessed July 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10640551/
42. AusPAR - Jemperli - dostarlimab - GlaxoSmithKline Australia Pty Ltd - Therapeutic Goods Administration (TGA), accessed July 30, 2025, https://www.tga.gov.au/sites/default/files/2023-02/auspar-jemperli-230210-pi.pdf
43. EMA Recommends Extending the Indications for Dostarlimab - ESMO, accessed July 30, 2025, https://www.esmo.org/oncology-news/ema-recommends-extending-the-indications-for-dostarlimab
44. EMA Accepts GSK's Application for Use of Jemperli Plus Chemotherapy for All Endometrial Cancer Patients - BioPharm International, accessed July 30, 2025, https://www.biopharminternational.com/view/ema-accepts-gsk-s-application-for-use-of-jemperli-plus-chemotherapy-for-all-endometrial-cancer-patients
45. Upfront Dostarlimab/Chemotherapy Yields Better Risk Reduction ..., accessed July 30, 2025, https://www.oncnursingnews.com/view/upfront-dostarlimab-chemotherapy-yields-better-risk-reduction-than-pembrolizumab-chemotherapy-in-nsclc
46. Strong Clinical Efficacy With Dostarlimab and Chemo in Advanced NSCLC, accessed July 30, 2025, https://www.targetedonc.com/view/strong-clinical-efficacy-with-dostarlimab-and-chemo-in-advanced-nsclc
47. The High-Resolution Structure Reveals Remarkable Similarity in PD ..., accessed July 30, 2025, https://www.mdpi.com/2227-9059/10/12/3154
48. Imfinzi, Keytruda Approved for Some Endometrial Cancers - NCI, accessed July 30, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2024/endometrial-cancer-durvalumab-pembrolizumab-chemotherapy
49. Expanded Role for Immunotherapy to Treat Endometrial Cancer - NCI, accessed July 30, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2023/immunotherapy-endometrial-cancer-pembrolizumab-dostarlimab
50. Jemperli vs Keytruda for endometrial cancer: What's the difference? - Everyone.org, accessed July 30, 2025, https://everyone.org/blog/jemperli-vs-keytruda-for-endometrial-cancer
51. Nivolumab in Treating Patients with Metastatic or Recurrent Uterine Cancer - NCI, accessed July 30, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2017-01524
52. Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer, accessed July 30, 2025, https://jitc.bmj.com/content/13/2/e010541
53. Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers, accessed July 30, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1391896/full
54. Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer, accessed July 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10507332/
55. Monoclonal Antibody Manufacturing Processes | Avantor, accessed July 30, 2025, https://www.avantorsciences.com/us/en/support/knowledge-center/monoclonal-antibody-production-process
56. How to produce monoclonal antibodies (mAbs) - Abcam, accessed July 30, 2025, https://www.abcam.com/en-us/knowledge-center/antibodies/monoclonal-antibody-production
57. Monoclonal Antibody Production, mAb - Molecular Devices, accessed July 30, 2025, https://www.moleculardevices.com/applications/monoclonal-antibody-production
58. Monoclonal antibody - Wikipedia, accessed July 30, 2025, https://en.wikipedia.org/wiki/Monoclonal_antibody